LeMaitre Vascular (LMAT) director receives new dividend equivalent rights grants

Rhea-AI Filing Summary

LeMaitre Vascular director John James O’Connor reported routine compensation-related grants of dividend equivalent rights. On June 4, 2026, he acquired several small awards of dividend equivalent rights tied to existing restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and carries a stated price of $0.00 per right. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights in total, which vest proportionately with the underlying stock and performance awards rather than representing open-market purchases or sales.

Insights

Equity compensation analyst

Director received small dividend-equivalent grants as standard equity compensation, with no open-market trading.

The reporting person, director John James O’Connor, acquired several small blocks of Dividend Equivalent Rights on June 4, 2026. These are compensation-linked derivatives tied to prior restricted stock unit and performance share unit grants, each recorded at $0.00 per right.

Footnotes state these rights accrued on awards granted on December 8, 2023, December 6, 2024, and December 10, 2025, and vest proportionately with those awards. Each right is the economic equivalent of one share of common stock, giving equity-like exposure without a cash transaction.

After the grants, O’Connor holds 5.0674 dividend equivalent rights directly. There are no sales, option exercises, or tax-withholding dispositions in this filing, making the activity routine and primarily informative about ongoing equity-based director compensation rather than signaling a change in sentiment.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider O'Connor John James

Role null

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	0.466	$0.00	--
Grant/Award	Dividend Equivalent Rights	0.558	$0.00	--
Grant/Award	Dividend Equivalent Rights	0.76	$0.00	--
Grant/Award	Dividend Equivalent Rights	0.86	$0.00	--
Grant/Award	Dividend Equivalent Rights	1.427	$0.00	--

Holdings After Transaction: Dividend Equivalent Rights — 5.067 shares (Direct, null)

Footnotes (1)

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Largest dividend equivalent grant: 1.4274 rights Total dividend equivalent rights after grants: 5.0674 rights Grant price per right: $0.00 per right +2 more

5 metrics

Largest dividend equivalent grant 1.4274 rights Grant on June 4, 2026 to director John James O’Connor

Total dividend equivalent rights after grants 5.0674 rights Director’s direct holdings following June 4, 2026 transactions

Grant price per right $0.00 per right All dividend equivalent rights granted June 4, 2026

Number of derivative transactions 5 transactions All coded as acquisitions of dividend equivalent rights

Economic equivalence 1 right = 1 share Each right equals one share of LMAT common stock economically

Key Terms

Dividend Equivalent Rights, restricted stock unit, performance share unit, economic equivalent

4 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

performance share unit financial

"These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

economic equivalent financial

"Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	06/04/2026		A		0.4658		(1)	(1)	Common Stock	0.4658	$0	5.0674	D
Dividend Equivalent Rights	(2)	06/04/2026		A		0.5579		(2)	(2)	Common Stock	0.5579	$0	4.8692	D
Dividend Equivalent Rights	(3)	06/04/2026		A		0.7595		(3)	(3)	Common Stock	0.7595	$0	4.2984	D
Dividend Equivalent Rights	(4)	06/04/2026		A		0.8599		(4)	(4)	Common Stock	0.8599	$0	4.4838	D
Dividend Equivalent Rights	(5)	06/04/2026		A		1.4274		(5)	(5)	Common Stock	1.4274	$0	2.6351	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LeMaitre Vascular (LMAT) report for director John James O’Connor?

LeMaitre Vascular reported that director John James O’Connor received several small grants of dividend equivalent rights on June 4, 2026. These rights are tied to prior stock-based awards and represent routine equity compensation rather than open-market share purchases or sales.

How many dividend equivalent rights does John James O’Connor hold after these LMAT transactions?

Following the June 4, 2026 grants, John James O’Connor directly holds 5.0674 dividend equivalent rights. Each right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the related stock or performance awards.

Are the June 4, 2026 LMAT insider transactions stock purchases or sales?

The June 4, 2026 insider transactions are not stock purchases or sales. They are Form 4 code “A” acquisitions of dividend equivalent rights granted at $0.00 per right, reflecting compensation accruals on existing equity awards rather than open-market trading activity.

What are dividend equivalent rights in the context of LeMaitre Vascular (LMAT) equity awards?

Dividend equivalent rights are compensation-related instruments that mirror dividends on underlying stock awards. For LMAT, each right is stated to be the economic equivalent of one share of common stock and accrues on restricted stock unit and performance share unit grants, vesting proportionately with those awards.

Which prior LMAT equity awards generated these dividend equivalent rights for John James O’Connor?

The dividend equivalent rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. The rights vest in proportion to those underlying awards, aligning director compensation with LeMaitre Vascular’s stock performance over time.